Alliance to Explore Angiogenesis-Modulating Genes

(DGI; Minneapolis, MN, USA) and AngioGenetics AB (Gothenburg, Sweden; ). They are hoping their study will lead to breakthrough treatments for such diseases as cancer and heart disease.

The companies say the collaboration can speed their process of identifying and validating genes important to angiogenesis. By combining their different competencies, they hope to achieve their goal much more quickly than could be accomplished by each company working alone. Revenues generated by their joint efforts will be shared. Angioenetics is focusing on early drug discovery for diseases in which angiogenesis is central to the pathology. DGI's mission is to discover and patent high-value intellectual property and provide gene-function information services.

"We are very satisfied having teamed up with DGI, pioneers in zebrafish knockdown technology, and we are confident this joint venture will lead to the generation of new valuable intellectual property on angiogenesis-regulating genes,” says Mattias Kalen, CEO of AngioGenetics.





Related Links:
Discovery Genomics
AngioGenetics